Myriad Genetics, Inc.
- MYGN
- NASDAQ
- Medical - Diagnostics & Research
- Molecular Diagnostics
- Genetic Testing (Cancer Risk)
$4.13
Today +3.64%Quote Oct 19, 2026, 06:40 PM UTC
−3.86%over the last month
Max drawdown −13.1%From 1-month high −13.1%3 months −32.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Myriad Genetics
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Exchange
NASDAQ
Employees
2,700
Founded
1991
Market value
$394.6M
Quote Oct 19
Floor
$3.97
3.8% below price
Resistance
$4.40
6.6% above price
Price vs analyst targets
37 analysts
Lowest target
$2.00Highest target
$8.00
$2.00Highest target
$8.00
- Price $4.13
- Average target $3.92
- Analysts' target range
Analysts' average target sits about 5% lower. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about MYGNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free